Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,672 | 251 | 1,413 |
| Samples | 605 | 123 | 478 |
| Peptides | 457 | 84 | 390 |
Function
AXL · AXL receptor tyrosine kinase
The protein encoded by this gene is a member of the Tyro3-Axl-Mer (TAM) receptor tyrosine kinase subfamily. The encoded protein possesses an extracellular domain which is composed of two immunoglobulin-like motifs at the N-terminal, followed by two fibronectin type-III motifs. It transduces signals from the extracellular matrix into the cytoplasm by binding to the vitamin K-dependent protein growth arrest-specific 6 (Gas6). This gene may be involved in several cellular functions including growth, migration, aggregation and anti-inflammation in multiple cell types. The encoded protein acts as a host cell receptor for multiple viruses, including Marburg, Ebola and Lassa viruses and is a candidate receptor for the SARS-CoV2 virus. [provided by RefSeq, Sep 2021].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 439 amino-acid changes on canonical ENST00000301178 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in AXL · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in AXL – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Melanoma | 11/210 5% | 109/1899 6% |
| Endometrial Carcinoma | 4/42 10% | 29/612 5% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Colorectal Carcinoma | 29/143 20% | 63/3239 2% |
| Unknown | 0/10 0% | 1/29 3% |
| Gastric Carcinoma | 1/74 1% | 40/1809 2% |
| Other Solid Cancers | 7/94 7% | 22/1515 1% |
| Mesothelioma | 3/62 5% | 1/165 1% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Neuroendocrine Tumour | 9/154 6% | 2/577 0% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 10/810 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 9/1390 1% |
| Bladder Carcinoma | 1/58 2% | 11/956 1% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Hepatocellular Carcinoma | 2/46 4% | 22/2210 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 16/1592 1% |
| Other Sarcomas | 0/69 0% | 7/699 1% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Non-Cancerous | 1/104 1% | 7/830 1% |
| Pancreatic Carcinoma | 2/89 2% | 11/1611 1% |
| Prostate Carcinoma | 2/13 15% | 14/2105 1% |
| Neuroblastoma | 2/87 2% | 8/1331 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 15/2550 1% |
Mutation Distribution
Where AXL is mutated · all tissues, split by cell line vs tissue
How many mutations in AXL were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,672 mutations in AXL
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|